Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M.

Lancet. 2010 Mar 27;375(9720):1100-8. doi: 10.1016/S0140-6736(09)62126-7. Epub 2010 Jan 21.

PMID:
20096450
2.

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

Arguedas A, Soley C, Lindert K.

N Engl J Med. 2010 Jan 28;362(4):370-2. doi: 10.1056/NEJMc0909988. Epub 2009 Dec 30. No abstract available.

3.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.

PMID:
20034605
4.

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, Nissen M, Marshall H, Booy R, Heron L, Hartel G, Lai M, Basser R, Gittleson C, Greenberg M.

JAMA. 2010 Jan 6;303(1):37-46. doi: 10.1001/jama.2009.1911. Epub 2009 Dec 21.

PMID:
20026597
5.

Large trials confirm immunogenicity of H1N1 vaccines.

Kelly H, Barr I.

Lancet. 2010 Jan 2;375(9708):6-9. doi: 10.1016/S0140-6736(09)62132-2. Epub 2009 Dec 15. No abstract available.

PMID:
20018366
6.

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M.

Lancet. 2010 Jan 2;375(9708):41-8. doi: 10.1016/S0140-6736(09)62026-2. Epub 2009 Dec 15.

PMID:
20018365
7.

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, Li RC, Xia SL, Zhao YL, Li FJ, Yan SH, Yin WD, An K, Feng DJ, Cui XL, Qi FC, Ju CJ, Zhang YH, Guo ZJ, Chen PY, Chen Z, Yan KM, Wang Y.

Lancet. 2010 Jan 2;375(9708):56-66. doi: 10.1016/S0140-6736(09)62003-1. Epub 2009 Dec 15. Erratum in: Lancet. 2010 May 15;375(9727):1694.

PMID:
20018364
8.

Future of flu vaccines. Expediting clinical trials in a pandemic.

Pollard AJ, Reiner A, John T, Sheasby E, Snape M, Faust S, Collinson A, Finn A, Heath PT, Miller E.

BMJ. 2009 Nov 10;339:b4652. doi: 10.1136/bmj.b4652. No abstract available.

PMID:
19903713
9.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.

PMID:
19835828
10.

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.

Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team.

N Engl J Med. 2009 Nov 12;361(20):1935-44. doi: 10.1056/NEJMoa0906695. Epub 2009 Oct 8.

11.

Recommendations for the administration of influenza vaccine in children allergic to egg.

Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO.

BMJ. 2009 Sep 15;339:b3680. doi: 10.1136/bmj.b3680. Review. No abstract available.

PMID:
19755545
12.

Reproducibility of serologic assays for influenza virus A (H5N1).

Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM.

Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754.

13.

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I.

N Engl J Med. 2009 Dec 17;361(25):2424-35. doi: 10.1056/NEJMoa0907650. Epub 2009 Sep 10.

14.

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM.

N Engl J Med. 2009 Nov 12;361(20):1945-52. doi: 10.1056/NEJMoa0906453. Epub 2009 Sep 10.

15.

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand.

Vaccine. 2009 Dec 9;27(52):7428-35. doi: 10.1016/j.vaccine.2009.07.102. Epub 2009 Aug 13.

PMID:
19683087
16.

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ; Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52. Erratum in: MMWR Recomm Rep. 2009 Aug 21;58(32):896-7.

17.

Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009.

[No authors listed]

Wkly Epidemiol Rec. 2009 Jul 24;84(30):301-4. English, French. No abstract available.

18.

Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.

Collin N, de Radiguès X; World Health Organization H1N1 Vaccine Task Force.

Vaccine. 2009 Aug 20;27(38):5184-6. doi: 10.1016/j.vaccine.2009.06.034. Epub 2009 Jun 27.

PMID:
19563891
19.

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

Barrett PN, Mundt W, Kistner O, Howard MK.

Expert Rev Vaccines. 2009 May;8(5):607-18. doi: 10.1586/erv.09.19. Review.

PMID:
19397417
20.

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team.

N Engl J Med. 2008 Jun 12;358(24):2573-84. doi: 10.1056/NEJMoa073121.

Supplemental Content

Support Center